RBC Capital analyst Leonid Timashev maintained a Buy rating on Praxis Precision Medicines yesterday and set a price target of $449.00.TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Timashev is a 5-star analyst with an average return of 27.9% and a 62.34% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Insmed, Revolution Medicines, and ADC Therapeutics.
In addition to RBC Capital, Praxis Precision Medicines also received a Buy from Guggenheim’s Yatin Suneja in a report issued on June 30. However, on the same day, Wells Fargo assigned a Hold rating to Praxis Precision Medicines (NASDAQ: PRAX).
Based on Praxis Precision Medicines’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $92.56 million. In comparison, last year the company had a GAAP net loss of $69.3 million
